Enterprise Value

23.06B

Cash

2.312B

Avg Qtr Burn

N/A

Short % of Float

3.21%

Insider Ownership

1.17%

Institutional Own.

98.97%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KRYSTEXXA Details
Chronic refractory gout

Approved

Quarterly sales

Approved

Quarterly sales

TEPEZZA (U.S) Details
Eye disease , Thyroid Eye Disease

Phase 3

Data readout

Phase 3

Data readout

Phase 3

Data readout

TEPEZZA (OPTIC-J/Japan) Details
Eye disease , Thyroid Eye Disease

Phase 3

Data readout

Phase 3

Initiation

HZN-825 Details
IPF (Idiopathic Pulmonary Fibrosis)

Phase 2b

Data readout

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

ADX-914 Details
Atopic dermatitis

Phase 2

Data readout

Dazodalibep (HZN-4920) Details
Kidney disease, Lupus nephritis, Autoimmune disease

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Update

HZN-457 Details
Chronic refractory gout

Phase 1

Data readout